Schroder Investment Management Group Sells 3,642 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Schroder Investment Management Group decreased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,311 shares of the medical equipment provider's stock after selling 3,642 shares during the quarter. Schroder Investment Management Group's holdings in Zimmer Biomet were worth $1,825,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. CKW Financial Group grew its holdings in Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after purchasing an additional 100 shares during the period. Romano Brothers AND Company boosted its position in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock worth $1,000,000 after purchasing an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its stake in shares of Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares during the period. M&T Bank Corp increased its position in Zimmer Biomet by 0.4% in the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after buying an additional 108 shares in the last quarter. Finally, Dakota Wealth Management raised its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after buying an additional 122 shares during the period. Institutional investors own 88.89% of the company's stock.

Remove Ads

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.95% of the company's stock.

Zimmer Biomet Stock Performance

ZBH traded up $0.04 on Friday, hitting $102.30. The company's stock had a trading volume of 2,275,065 shares, compared to its average volume of 1,629,112. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $127.32. The firm has a market cap of $20.36 billion, a P/E ratio of 22.99, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company's 50 day simple moving average is $106.31 and its 200-day simple moving average is $107.04.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company earned $2.20 earnings per share. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZBH shares. JMP Securities reissued a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reissued a "hold" rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Finally, Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.